Interestingly, cholinergic transmission at the neuromuscular junction can be boosted via potassium channel blockade with fampridine (4-aminopyridine) and has been clinically indicated in disorders such as myasthenia gravis and multiple sclerosis (Kostadinova and Danchev, 2019). This evidence concerns the gene KCNA3 and myasthenia gravis.